The first stop for professional medicines advice

Guidance

627 results

Applied filters

MSATS - Safer use of insulin

26 March 2025Discussion of key current medication safety challenges within healthcare with a focus on the safe use of insulin; inspiring partnership across the system.

Labelling and packaging medicines supplied by dental teams

26 March 2025Requirements for labelling and packaging medicines before supply by dental teams are detailed in legislation and depend on the classification of the medicine

Supplying medical devices: advice for dental teams

26 March 2025Advice on supplying medical devices directly to NHS and private patients by dentists, dental hygienists and dental therapists.

Supplying P and GSL medicines: advice for dental teams

26 March 2025Advice on supplying P and GSL medicines to NHS and private patients by dentists, dental hygienists and dental therapists.

Supplying Prescription Only Medicines: advice for dental teams

26 March 2025Advice on supplying prescription only medicines (POMs) to NHS and private patients by dentists, dental hygienists and dental therapists.

Supplying medicines and medical devices: advice for dental teams

26 March 2025Supply of medicines by dentists and dental care professionals depends on the class of medicine, legal mechanism used and requires a local governance framework.

Developing opioid safety across a system

26 March 2025Strategies and signposting to support safer use of opioids for chronic, non-cancer pain.

Somatic Cell Therapy Medicinal Products - Pharmacy Institutional Readiness Guidance

25 March 2025This document outlines key areas for focus of pharmaceutical expertise prior to an organisation implementing Somatic Cell Therapy Product.

Pharmacogenomics: resources to support answering questions

21 March 2025Suggested resources to help healthcare professionals find information to answer questions about pharmacogenomics.

Ex-Vivo (cell based) GMO Gene Therapy Medicinal Products - Pharmacy Institutional Readiness Guidance

20 March 2025This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing Ex-Vivo genetically modified organism (GMO) Gene Therapy.